Zhongsheng Pharmaceutical: The registration certificate of Ambraxol Hydrochloride Oral Solution has been approved.

Crowd pharmaceuticals announced that it recently received the "Drug Registration Certificate" for the oral solution of ambroxol hydrochloride approved and issued by the National Medical Products Administration. The oral solution of ambroxol hydrochloride is a category B medical insurance drug, with sales in public hospitals and urban retail pharmacies in China expected to reach 7.11 billion yuan, 8.18 billion yuan, and 8.5 billion yuan from 2022 to 2024. This approval marks the product's achievement in passing the consistency evaluation of chemical generic drugs, further enriching the company's product line in the field of respiratory system treatment.